Navigation Links
Drug That Lowers Resting Heart Rate Being Tested
Date:8/22/2007

Slower heartbeat linked to better cardiac outcome, scientists report

WEDNESDAY, Aug. 22 (HealthDay News) -- Can a drug designed solely to lower the resting heart rate improve treatment of cardiovascular conditions such as heart failure and coronary artery disease?

Answers to that question are expected next year from two major international trials that are testing the drug, said Dr. Jeffrey S. Borer, a professor of cardiovascular medicine at Weill Cornell Medical College in New York City.

The resting heart rate is the natural heartbeat measured after someone has been at rest for at least 10 minutes. A number of studies have linked a lower resting heart rate with better outcomes among those with cardiovascular disease, said Borer, a member of a group summarizing that evidence in the Aug. 28 issue of the Journal of the American College of Cardiology.

"That group of authors is involved in the evaluation of a new approach to heart rate slowing," Borer said. "It allows us for the first time to determine the pure effect of heart rate slowing on cardiac health."

The new approach uses a drug called ivabradine, which acts specifically on the cells of the sino-atrial node, the heart's natural pacemaker. Other drugs, such as beta blockers, can slow the resting heart rate, but they have other effects that blur the impact of a slowed resting heart rate.

Ivabradine has been approved in Europe for treatment of the chest pain called angina, but Servier Laboratories, the French company that markets the drug, has not applied for U.S. approval because it has no American subsidiary.

A footnote to the journal paper says all of its 10 authors "have received honoraria and many have received research grants from Servier Laboratories, and all authors are a part of the advisory board of ivabradine."

But those physicians, who describe themselves as members of the Heart Rate Working Group, are interested more in the general effects of resting heart rate than in any one drug, Borer said.

"We have been publishing for several years, because it became apparent that the potential importance of resting heart rate in determining prognosis is not so well understood," he said.

Perhaps the first study to indicate the possible importance of the resting heart rate was done during World War II, looking at the medical records of 25,000 army officers, Borer said. "Those with a resting heart rate above 100, about 300 of them, had a very poor long-term outcome," he noted.

In recent years, studies done in Norway have looked at possible beneficial effects of lowering the resting heart rate, using drugs such as beta blockers, Borer said. Studies of people with heart failure, the progressive loss of the heart's ability to pump blood, and of those who had suffered heart attacks, did show a benefit from slowing the heart rate, he added.

And a report on 25,000 cardiac patients done by Dr. Jean-Claude Tardif, of the Montreal Heart Institute, showed "a clear distinction in outcome based on resting heart rate," Borer added.

While there obviously are differences among individuals as to the best resting heart rate, "it is probably best if it is somewhat lower than 70" for an adult, he said.

Definitive evidence on the value of using a drug to lower the resting heart rate is expected from the two international trials now in progress, one including people with coronary artery disease, the other including people with heart failure, Borer said.

Results of those studies should be available by the late summer of 2008, he said.

More information

Learn more about the resting heart rate from the U.S. National Library of Medicine.



SOURCES: Jeffrey S. Borer, professor, cardiovascular medicine, Weill Cornell Medical College, New York City; Aug. 28, 2007, Journal of the American College of Cardiology


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Brisk Walking lowers memory loss in women
2. B Vitamin protects and lowers toxicity of Arthritis Drug
3. Estrogen lowers cancer risk
4. Lecithin lowers cholesterol absorption in body
5. Salt reduction lowers blood pressure
6. Tea Pill Lowers Cholesterol
7. Aspirin Lowers Leukemia Risk
8. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
9. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
10. Exercise lowers Risk of Ovarian Cancer
11. Fish rich diet lowers leptin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... Tennessee (PRWEB) , ... February 13, 2016 , ... ... the Infusion Nurses Society (INS) states that vein visualization technology should be used ... by healthcare facilities around the world, the INS Standards mandate the use of ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Eli Lilly and Company (NYSE: LLY ) today ... disodium) vitamin regimen patent would not presently be infringed by ... , Italy and ... with dextrose solution.  --> ... Appeal held that Lilly,s patent would be indirectly infringed by ...
(Date:2/12/2016)... LOUISVILLE, Ky. , Feb. 12, 2016 ... it has completed a $47.1 million Series ... investors Cormorant Asset Management, Hillhouse Capital Group ... investors Morningside Venture Investments, AJU IB Investment, ... will be used to further advance clinical ...
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
Breaking Medicine Technology: